Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the activity of Brentuximab vedotin in refractory germ cell tumors.


Clinical Trial Description

Complete responses with third-line or later salvage chemotherapy (CT) for germ cell tumors (GCT) range 0% to 10% and are usually short-lived and nearly all patients (pts) progressing after multiple courses or high-dose CT will ultimately die from progressive disease.

Cluster of Differentiation antigen-30 (CD30) is expressed by untreated embryonal carcinoma (ECA) thus lending support to a rationale for a targeted approach. The investigators retrospectively re-assessed ECA to strongly retain CD30 staining in most cases (>70%), even after multiple courses or high-dose CT. Moreover, a negative prognostic value of CD30 expression by residuals after CT, particularly in the salvage setting, was set. Brentuximab vedotin is an antibody-drug conjugate consisting of the chimeric anti-CD30 antibody chemically conjugated to an antitubulin synthetic analog (MMAE).

Proof of activity will provide rationale for developing first-line chemo-immunotherapy or maintenance immunotherapy for selected high-risk pts. The primary objective of the study will be the activity of Brentuximab vedotin in refractory GCT. Secondary objectives will include safety and survival.

24 pts with biopsy-proven CD30 positive GCT will receive intravenous Brentuximab vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity. Further eligibility requirements will include failure of 2 or 3 platinum-based CT (prior high-dose CT is allowed). All pts will undergo measurement of serum tumor markers, a computed tomography and a positron emission tomography (PET) scan every weeks. An optimal Simon's 2-stage design will be applied. The primary endpoint is the objective response-rate (ORR). An ORR of 5% is not promising, while a 25% rate will be promising. In stage 1, 9 evaluable patients will be accrued. The type I and II error are both set at 10%.

Additional post-treatment tissue will be available for pts undergoing surgery in the treatment time-course. Tissue array blocks will be constructed from samples of all pts. Assessment will include mutational analysis of most-frequently mutated genes. Two serum aliquots will be collected at baseline and during/end of treatment to assess circulating CD30. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01851200
Study type Interventional
Source Fondazione Michelangelo
Contact
Status Completed
Phase Phase 2
Start date May 2013
Completion date September 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00996710 - Genomic Structural Variation in Cancer Susceptibility
Active, not recruiting NCT01453660 - Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
Completed NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Phase 2
Not yet recruiting NCT06275854 - YASU Research Registry: For Young Adults With Cancer
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Completed NCT02303015 - Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors
Not yet recruiting NCT06329323 - SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours